Due to the high frequency of mutations in the synaptic scaffolding protein SHANK3 (more than 1 in 50) in patients with ASD and intellectual disability, mutation screening of SHANK3 has been suggested for consideration in clinical practice (Leblond et al., 2014). The gene discussed is SHANK3; the disease is Intellectual disability.